| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_PRKCI_0010100 | Intron-Intron | chr3:170011297-170013658 | chr3:170293509-170295870 | 2362 nt | 0.4301 |
| hsa_chr3_0356500 | Intergenic-Intergenic | chr3:170020931-170021267 | chr3:170303143-170303479 | 337 nt | 0.2938 |
| hsa_chr3_0356600 | Intergenic-Intergenic | chr3:170022141-170023434 | chr3:170304353-170305646 | 1294 nt | 0.3053 |
| hsa_chr3_0356700 | Intergenic-Intergenic | chr3:170023091-170023713 | chr3:170305303-170305925 | 623 nt | 0.3291 |
A study in humans demonstrated that circPRKCI is significantly upregulated in lung adenocarcinoma and squamous cell carcinoma tissues, where it promotes cancer cell proliferation, migration, and invasion by acting as a sponge for miR-545 and miR-589 to elevate E2F7 expression [Zhang et al. DOI:10.1038/s41418-022-00948-7]. A review of human studies indicates that the circPRKCI is upregulated in oesophageal squamous cell carcinoma tissues and its expression is associated with tumor differentiation and stage, while its downregulation suppresses cancer cell proliferation and migration [Lee et al. DOI:10.1016/j.biopha.2018.12.052].